INAB RSI Chart
Last 7 days
-1.9%
Last 30 days
-9.6%
Last 90 days
-13.3%
Trailing 12 Months
-50.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 13, 2023 | graff jeremy r. | acquired | - | - | 2,049 | - |
Dec 13, 2023 | brandt peter c. | acquired | - | - | 81,967 | - |
Dec 13, 2023 | roemer alan s. | acquired | - | - | 102,459 | - |
Dec 13, 2023 | lamb lawrence | acquired | - | - | 1,639 | evp and cso |
Dec 13, 2023 | ho william tai-wei | acquired | - | - | 81,967 | president and ceo |
Dec 13, 2023 | epperly corinne | acquired | - | - | 81,967 | - |
Dec 13, 2023 | mccall patrick | acquired | - | - | 20,492 | chief financial officer |
Dec 13, 2023 | goswami trishna | acquired | - | - | 4,098 | chief medical officer |
Dec 13, 2023 | rochlin kate | acquired | - | - | 12,295 | chief operating officer |
Sep 13, 2023 | graff jeremy r. | bought | 2,375 | 0.95 | 2,500 | - |
Which funds bought or sold INAB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 22, 2024 | Stonegate Investment Group, LLC | unchanged | - | -36,000 | 212,400 | 0.01% |
Apr 19, 2024 | Westside Investment Management, Inc. | reduced | -17.24 | -5,850 | 14,160 | -% |
Apr 16, 2024 | Overbrook Management Corp | unchanged | - | -6,751 | 39,832 | 0.01% |
Apr 15, 2024 | Wela Strategies, Inc. | new | - | 21,887 | 21,887 | 0.01% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 23.02 | 222,763 | 575,040 | -% |
Feb 14, 2024 | Royal Bank of Canada | added | 129 | - | - | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 27,334 | 27,334 | -% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | unchanged | - | 26,623 | 108,057 | -% |
Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | new | - | 58,410 | 58,410 | -% |
Unveiling IN8bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to IN8bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.6B | 6.8B | -9.03 | 6.22 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.9B | 1.8B | -42.88 | 10.32 | ||||
BMRN | 15.8B | 2.5B | 76.99 | 6.4 | ||||
INCY | 11.9B | 3.8B | 15.95 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.6B | 396.6M | -10.5 | 14 | ||||
BBIO | 4.8B | - | -7.27 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.83 | 13.11 | ||||
ARWR | 2.9B | 240.7M | -9.66 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.81 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.07 | 4.5 | ||||
NVAX | 652.2M | 983.7M | -1.2 | 0.66 | ||||
CRBP | 390.9M | 881.7K | -8.76 | 466.16 | ||||
INO | 270.2M | 4.9M | -2 | 55.51 | ||||
IBIO | 6.4M | 2.1M | -0.24 | 2.14 |
IN8bio Inc News
Balance Sheet | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | 28.6% | 34.00 | 26.00 | 30.00 | 25.00 | 33.00 | 38.00 | 31.00 | 37.00 | 42.00 | 47.00 | 18.00 | 21.00 |
Current Assets | 48.8% | 25.00 | 17.00 | 19.00 | 14.00 | 22.00 | 30.00 | 27.00 | 33.00 | 39.00 | 44.00 | 12.00 | 18.00 |
Cash Equivalents | 64.3% | 22.00 | 13.00 | 17.00 | 11.00 | 18.00 | 28.00 | 26.00 | 32.00 | 37.00 | 41.00 | 12.00 | 18.00 |
Net PPE | -6.0% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | 3.8% | 9.00 | 8.00 | 8.00 | 8.00 | 10.00 | 9.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 |
Current Liabilities | 15.1% | 5.00 | 5.00 | 4.00 | 4.00 | 6.00 | 5.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 |
Shareholder's Equity | 40.4% | 25.00 | 18.00 | 22.00 | 17.00 | 23.00 | 30.00 | 27.00 | 33.00 | 38.00 | 43.00 | - | - |
Retained Earnings | -9.1% | -91.22 | -83.62 | -76.45 | -68.74 | -61.21 | -53.41 | -46.01 | -38.84 | -32.69 | -26.84 | -23.45 | -18.04 |
Additional Paid-In Capital | 14.6% | 116 | 101 | 98.00 | 86.00 | 84.00 | 83.00 | 73.00 | 72.00 | 71.00 | 70.00 | 2.00 | 1.00 |
Shares Outstanding | 35.4% | 43.00 | 32.00 | 31.00 | 25.00 | 25.00 | 20.00 | 19.00 | 19.00 | 19.00 | 7.00 | 4.00 | 4.00 |
Float | - | - | - | 23.00 | - | - | - | 6.00 | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | 15.1% | -4,850 | -5,713 | -5,338 | -7,439 | -7,949 | -5,741 | -5,872 | -4,559 | -2,176 | -6,365 | -2,461 | -2,507 | - | - | - |
Share Based Compensation | 1.0% | 1,252 | 1,240 | 1,019 | 859 | 922 | 897 | 884 | 764 | 965 | 477 | 392 | 361 | 303 | 16.00 | 20.00 |
Cashflow From Investing | 6.5% | -72.00 | -77.00 | -22.00 | -429 | -1,263 | -1,764 | -425 | -253 | -156 | - | - | - | - | - | - |
Cashflow From Financing | 708.2% | 13,352 | 1,652 | 11,493 | 547 | -253 | 9,410 | -67.00 | -102 | -1,212 | 35,194 | -592 | -435 | - | - | - |
Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development | $ 16,827 | $ 14,062 |
General and administrative | 13,510 | 14,459 |
Total operating expenses | 30,337 | 28,521 |
Loss from operations | (30,337) | (28,521) |
Other Income | 330 | 0 |
Net loss | $ (30,007) | $ (28,521) |
Net loss per share - basic | $ (1) | $ (1.36) |
Net loss per share - diluted | $ (1) | $ (1.36) |
Weighted-average number of shares used in computing net loss per common share - basic | 29,864,932 | 20,967,955 |
Weighted average number of shares used in computing net loss per share basic and diluted | 29,864,932 | 20,967,955 |
Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash | $ 21,282 | $ 18,182 |
Prepaid expenses and other current assets | 3,343 | 4,052 |
Total Current Assets | 24,625 | 22,234 |
Non-current assets | ||
Property and equipment, net | 3,514 | 4,397 |
Construction in progress | 182 | 29 |
Restricted cash | 256 | 252 |
Right of use assets - financing leases | 1,364 | 1,691 |
Right of use assets - operating leases | 3,513 | 4,181 |
Other non-current assets | 255 | 255 |
Total Non-Current Assets | 9,084 | 10,805 |
Total Assets | 33,709 | 33,039 |
Current liabilities | ||
Accounts payable | 924 | 2,091 |
Accrued expenses and other current liabilities | 2,955 | 2,342 |
Less: short-term lease liability | 694 | 682 |
Short-term operating lease liability | 820 | 707 |
Total Current Liabilities | 5,393 | 5,822 |
Long-term lease liability | 525 | 811 |
Long-term operating lease liability | 2,854 | 3,674 |
Total Non-Current Liabilities | 3,379 | 4,485 |
Total Liabilities | 8,772 | 10,307 |
Stockholders' Equity | ||
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at December 31, 2023 and 2022. No shares issued and outstanding | 0 | 0 |
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at December 31, 2023 and 2022; 43,287,325 and 24,545,157 shares issued and outstanding at December 31, 2023 and 2022, respectively | 4 | 3 |
Additional paid-in capital | 116,152 | 83,941 |
Accumulated deficit | (91,219) | (61,212) |
Total Stockholders' Equity | 24,937 | 22,732 |
Total Liabilities and Stockholders' Equity | $ 33,709 | $ 33,039 |